Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients

Documenti analoghi

• Total lesion glycolysis is a promising predictor of chemo‐response in pancreatic cancer patients treated with neoadjuvant chemotherapy prior to surgery
  di: Sooin Byeon, et al.
  Pubblicazione: (2025)
• FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival
  di: Nathalie B. Rasko, et al.
  Pubblicazione: (2025)
• The Surgeon's Hand: The Most Sensitive Instrument in Detection of Small Bowel Neuroendocrine Tumors
  di: Jessica Falon, et al.
  Pubblicazione: (2026)
• Gene Expression Profiling of Pancreatic Ductal Adenocarcinoma Arising From Intraductal Papillary Mucinous Neoplasms of the Pancreas
  di: William A. Ziaziaris, et al.
  Pubblicazione: (2024)
• Preservation of pancreatic tail in traumatic pancreatic neck injury
  di: Alex Boue, et al.
  Pubblicazione: (2024)